Abstract
In the present study, we investigated the clinical effects of image-guided iodine-125 (125I) seed on unresectable pancreatic cancer. Twenty-five patients with unresectable pancreatic cancer were enrolled in this study, including 13 patients with seed implantation and 12 patients as control. The survival status, clinical benefits, objective curative effects, and relevant tumor markers were analyzed to assess the feasibility and safety of interstitial 125I seed implantation. We found that the clinical benefit rate of the seed implantation group is 92.3 % (12/13), compared with 41.7 % (5/12) in the control, and the difference was statistically significant (p < 0.01). Compared with control, patients with seed implantation had significantly shorter operative time, less bleeding, higher albumin, shorter periods to bowel movement, and normal diet as well as lower risk of complications (p < 0.001). The differences of objective curative effects adverse effects, complications, and median survival between these two groups were not significant statistically (p > 0.05). In conclusion, 125I seed implantation provides a safe and effective method to inhibit the tumor development, relieve pain, and improve quality of life for unresectable pancreatic cancer. These findings need to be validated by conducting further studies with larger cohorts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13(1):66–74.
Majumder S, Chubineh S, Birk J. Pancreatic cancer: an endoscopic perspective. Expert Rev Gastroenterol Hepatol. 2012;6(1):95–103.
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
Baron TH, Kozarek RA. Preoperative biliary stents in pancreatic cancer-proceed with caution. N Engl J Med. 2010;362(2):170–2.
Furuse J, Kinoshita T, Kawashima M, et al. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer. 2003;97:1346–52.
Wang JJ, Jiang YL, Li JN, et al. Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2009;28:1–6.
Wang H, Wang J, Jiang Y, et al. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J Exp Clin Cancer Res. 2013;32(1):106.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer. 2009;45:228–47.
Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline. Gan To Kagaku Ryoho. 2009;36(13):2495–501.
Liang J, Xi JW, Pan HJ, et al. Effect and mechanism of 125I radioactive particles interposed radiotherapy between organizations on lung cancer. Chin-Ger J Clin Oncol. 2013;12(12):1245–4.
Zhuang HQ, Wang JJ, Liao AY, et al. The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res. 2009;28:12.
Ma JX, Jin ZD, Si PR, et al. Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth. J Exp Clin Cancer Res. 2011;30:35.
Ma ZH, Yang Y, Zou L, et al. 125I seed irradiation induces upregulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts. J Exp Clin Cancer Res. 2012;31:61.
Syed AM, Puthawala AA, Neblett DL. Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer. 1983;52:808–13.
Liu K, Zhang W, Liu SY, et al. Comparison of iodine-125 seed implantation and pancreaticoduodenectomy in the treatment of pancreatic cancer. Int J Med Sci. 2014;11(9):893–6.
Wang ZM, Liu Y, Liu FJ, et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol. 2010;20(7):1786–91.
Ioka T, Nakamura S, Nishiyama K. A randomized phase II study of gemcitabine 1000 mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2010;78:S102.
Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys. 1989;17:931–5.
Acknowledgments
We gratefully thank other members of Yang Lab for their critical reading of this paper and valuable suggestions.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.
An erratum to this article is available at http://dx.doi.org/10.1007/s13277-017-5487-6.
About this article
Cite this article
Niu, H., Zhang, X., Wang, B. et al. RETRACTED ARTICLE: The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer. Tumor Biol. 37, 2219–2223 (2016). https://doi.org/10.1007/s13277-015-4045-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-4045-3